Loading...
Market
Tezspire's market approval status by end of 2025
2
Resolution / Starting Odds
Approved in US only • 25%
Approved in EU only • 25%
Approved in both US and EU • 25%
Not approved in US or EU • 25%
Regulatory approval announcements from FDA, EMA, and other major health authorities
Story
Amgen and AstraZeneca Report Positive Phase 3 WAYPOINT Results for Tezspire in CRSwNP, Meeting Primary Endpoints
Nov 8, 2024, 07:11 AM
Amgen and AstraZeneca have announced positive top-line results from their Phase 3 WAYPOINT trial evaluating Tezspire for the treatment of adults with chronic rhinosinusitis with nasal polyps (CRSwNP). The trial met both co-primary endpoints, demonstrating a statistically significant reduction in nasal polyp size. This marks a significant advancement in treatment options for patients suffering from this condition. The companies' stocks, $AMGN and $AZN, are likely to be impacted by this development.
View original story
Similar markets
Approved in US only • 33%
Approved in US and one other major market • 33%
Approved in US and multiple other major markets • 33%
Approved in UK only • 25%
Approved in UK and EU • 25%
Approved in UK, EU, and USA • 25%
Not approved in any major market • 25%
SMA Type 3 • 25%
SMA Type 2 • 25%
Both SMA Type 2 and 3 • 25%
Other • 25%
European Union • 25%
United Kingdom • 25%
Australia • 25%
Other • 25%
